Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins

Not Applicable

Completed

• Conditions: Corona Virus Disease 2019 (COVID-19)
• Interventions: Drug: Tocilizumab

• Registration Number: NCT04690920
• Lead Sponsor: University of Lahore

Brief Summary

IL-6 is an inflammatory marker, secrete by the cells in many pathological conditions like COVID-19 pneumonia. Interleukin 6 bind with its receptors (IL-6R) on cells surface and recruited a protein for its activation known as gp-130. Activated receptors send signals to nucleus through secondary messenger system and up regulate the expression of IL-6/GP130 domain. Total of two hundred (n=200) participants were included in the current study and divided equally in four groups. Group B is given Tocilizumab and Group C is treated with Remdesivir along with the approved standard treatment. Group D is only Given standard therapy and Group A constituted normal healthy age and sexed matched participants. Levels of gp-130 were estimated by commercially available ELISA kit. To estimate the relationship of severity of disease with gp-130 and IL-6 Pearson's correlations was used. Sensitivity and specificity for what purpose

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-23
• Status Verified: 2020-12
• Primary Completion: 2020-12-10
• Study Completion: 2020-12-10
• Study First Submitted: 2020-12-19
• Study First Submitted QC: 2020-12-30
• Last Update Submitted: 2020-12-30
• Study First Posted: 2020-12-31
• Last Update Posted: 2020-12-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Admitted diagnosed cases of COVID-19 infection on real time polymerase chain reaction (RT-PCR) Both male and female were included All participants were on oxygen therapy

Exclusion Criteria

Asthmatics pulmonary fibrosis chronic obstructive pulmonary disease (COPD) Allergic to remdesivir Allergic to Actemra Refused to take consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Standard Treatment	Tocilizumab	-
Remdesivir	Tocilizumab	-
Tocilizumab	Tocilizumab	-

Primary Outcome Measures

Name	Time	Method
Ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen	7 days

Secondary Outcome Measures

Name	Time	Method
Hospital stay	15 days
Viral load	7-15 days	by RT-PCR
Oxygen demand	7-15 days

Trial Locations

Locations (1)

The University of Lahore; 🇵🇰 Lahore, Punjab, Pakistan